http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2737230-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef2e9f5ce8630d9b282043b8d060caff |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4174 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4174 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-64 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4174 |
| filingDate | 2011-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22cbce8c477f3d5802189fcb11ba68d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96c7a16f619968af7c285c6eadc4e01e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c05636a0a90c6f6d04fc51029072241 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5b0dec2aef32c68121d2d810e193acd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_556748843d26b1f6693353a0f9e8d7a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d63b967ad9b0da1f01aeeb1adddeb357 |
| publicationDate | 2020-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2737230-T3 |
| titleOfInvention | Pro-drugs ester of [3- (1- (1H-imidazol-4-yl) ethyl) -2-methylphenyl] methanol to treat retinal diseases |
| abstract | A composition comprising a compound of Formula I for use in a method of treating age-related macular degeneration in a human patient in need of such treatment, which comprises administering a therapeutically effective amount of the composition comprising a compound of Formula I , its individual enantiomers, its individual diastereoisomers, its hydrates, its solvates, its crystalline forms, its individual tautomers or a pharmaceutically acceptable salt thereof, ** Formula ** wherein R1 is H or C1-3 alkyl; R2 is H or C1-3 alkyl; R3 is H, C1-10 alkyl, heterocycle or aryl; and R is C1-10 alkyl, heterocycle or aryl, wherein "alkyl" means a saturated monovalent alkane moiety having linear or branched alkane moieties or combinations thereof, which may be optionally substituted by amino groups, aryl groups, halogens, and a methylene (-CH2-) may be substituted by carbonyl, -NH-, carboxyl, amide, sulfur or by oxygen, and "heterocycle" means a 5-10 membered monocyclic or bicyclic ring, aromatic or non-aromatic, containing the minus a heteroatom selected from O or N or S or combinations thereof, disrupting the carbocyclic ring structure, which may optionally be substituted by C1-6 alkyl, amino, halogen, -O (C1-6 alkyl), -OC (O ) (C1-6 alkyl), -C (O) O (C1-6 alkyl), -NHC (O) (C1-6 alkyl), - C (O) NH (C1-6 alkyl), -S (alkyl C1-6), and "aryl" means an organic moiety derived from an aromatic hydrocarbon consisting of a monocyclic or bicyclic ring containing 6-10 ca atoms carbon by removal of a hydrogen atom, such as phenyl or naphthyl, which may be optionally substituted by, but not limited to, C1-6 alkyl groups, amino, halogen, -O (C1-6 alkyl), -OC (O ) (C1-6 alkyl), - C (O) O (C1-6 alkyl), -NHC (O) (C1-6 alkyl), -C (O) NH (C1-6 alkyl) and -S (alkyl C1-6). |
| priorityDate | 2010-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 155.